Written by the Nuvirox Research Team
Key Points
- The HF-AF ENERGY trial is an ongoing study testing whether nicotinamide riboside reduces atrial fibrillation (AF) burden in heart failure patients with ischemic heart disease.
- The trial's rationale rests on research showing reduced NAD+ levels contribute to mitochondrial dysfunction and cardiomyocyte impairment in heart failure and AF.
- This is a prospective interventional study with a 36-month planned duration — meaning results are not yet available, and patience is genuinely required here.
Short answer: a real, purpose-built clinical trial is testing this exact question right now, but it hasn't reported results yet. The mechanistic case is genuinely well-constructed; the outcome is still an open question, and it's worth understanding both halves of that sentence carefully rather than just the reassuring first part.
Why atrial fibrillation and NAD+ intersect
Atrial fibrillation (AF) — an irregular, often rapid heart rhythm — is common in heart failure patients with reduced ejection fraction, and its presence is associated with increased risk of stroke, hospitalization, and mortality. Research has found that reduced NAD+ levels contribute to mitochondrial dysfunction and DNA damage in heart failure and AF, which in turn impairs the heart muscle cells (cardiomyocytes) responsible for maintaining a normal rhythm. Heart tissue is particularly energy-demanding given its constant, rhythmic contraction, which is part of why mitochondrial and NAD+-related dysfunction has drawn specific research interest in cardiac arrhythmias rather than being treated as merely a generic aging-related finding applicable everywhere equally.
Study snapshot
| Trial name | HF-AF ENERGY Trial |
| Population | Heart failure patients with reduced ejection fraction and atrial fibrillation, ischemic heart disease |
| Design | Prospective interventional study; retrospective 4-month observation period + 4-month intervention period |
| Primary objective | Whether NR normalizes blood-based mitochondrial function markers and reduces AF burden |
| Approval | Erasmus Medical Center medical ethics committee |
What the trial is actually designed to measure
Conducted at Erasmus Medical Center, the trial's primary objective is to investigate whether NR normalizes blood-based mitochondrial function markers and energy metabolites of the NAD+ metabolome (including the NAD+/NADH ratio) in this patient population. Its secondary objective — the one most directly relevant if you're asking "does this help AF?" — is to examine whether NR reduces the burden of AF episodes in patients with ischemic heart disease. The study is structured with an initial retrospective observation period followed by an active intervention period, a design intended to establish each patient's own baseline before assessing treatment effects. This before-and-after, within-patient comparison approach is a reasonably rigorous way to account for the natural variability in AF episode frequency that occurs even without any treatment change, which can otherwise make a treatment's true effect harder to isolate.
The broader research context behind this trial
This trial doesn't exist in isolation — it builds on a broader body of work examining NAD+ decline in various forms of heart disease. Separate preclinical research has found that nicotinamide (a related NAD+ precursor) can rapidly restore cardiac NAD+ following cardiac arrest and ischemia-reperfusion injury in animal models, improving contractile recovery and survival. Other research has examined nicotinamide riboside's potential role in dilated cardiomyopathy and in protecting kidney function after heart attack in animal models, reflecting a fairly active broader research thread connecting NAD+ biology to multiple aspects of cardiovascular disease — of which AF-specific human trial data remains one still-unanswered piece.
What this doesn't tell you yet
Because this trial has not completed and reported results, there is currently no answer — positive or negative — to whether NAD+ precursor supplementation actually reduces AF episodes or improves heart failure outcomes in this population. The trial's rationale is grounded in real, peer-reviewed mechanistic research on NAD+ decline in heart failure and AF, but rationale is not the same as a result. It's also worth keeping in mind that AF has multiple underlying drivers beyond mitochondrial dysfunction — including structural heart changes, electrical remodeling, and other risk factors like high blood pressure and sleep apnea — so even if this trial eventually shows a positive signal, NAD+ supplementation would likely represent one piece of a larger management picture rather than a standalone fix.
What this means if you have AF or heart failure
Atrial fibrillation and heart failure are serious cardiovascular conditions managed through prescribed medications (which may include rate or rhythm control drugs, anticoagulants, and heart-failure-specific therapies), and sometimes procedures like ablation. None of that should be paused or substituted based on an ongoing trial without reported results. If you're a candidate for a trial like this one, or simply curious how it might relate to your treatment, that's a conversation for your cardiologist, who can weigh your specific cardiac history and current medication regimen. For related cardiovascular research with more mature human data, our broader review of NAD+ and heart health and NAD+ and circulation cover a completed peripheral artery disease trial with actual reported outcomes.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Does NAD+ supplementation reduce atrial fibrillation episodes specifically?
That's exactly what the HF-AF ENERGY trial is designed to find out, and results are not yet available.
Is this trial only for people with both heart failure and AF together?
Yes ��� the trial specifically enrolls heart failure patients with reduced ejection fraction who also have atrial fibrillation and ischemic heart disease, not AF in isolation or in otherwise healthy hearts.
How long is the trial expected to run?
It's designed as a full 36-month prospective interventional study, following an initial retrospective observation period.
Should someone with AF take an NAD+ supplement now, before the trial reports results?
That's a decision to make with your cardiologist, particularly given that AF management often involves anticoagulation and rhythm-control medications where interactions and monitoring matter.
What other factors contribute to atrial fibrillation besides mitochondrial dysfunction?
AF has multiple recognized drivers, including structural changes in the heart, electrical remodeling of heart tissue, high blood pressure, sleep apnea, and excessive alcohol use, among others — mitochondrial and NAD+-related dysfunction is one piece of a broader, multifactorial picture.
Where can I check on this trial's progress?
Registered trials like this one typically post status updates through their official clinical trial registry listing, which is the most reliable place to check rather than secondary summaries or news coverage that may lag behind the actual current trial status.
The bottom line: the biological rationale for this trial is genuinely strong, built on real prior research about NAD+ decline in failing, arrhythmic hearts — but the actual test of whether that translates into fewer AF episodes is still running. That's worth watching, not yet worth acting on, and we'll aim to update this article once the trial's results become available.
References
- The HF-AF ENERGY Trial: Nicotinamide Riboside for the Treatment of Atrial Fibrillation in Heart Failure Patients. PMC10721700.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.